SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) saw a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 260,200 shares, a drop of 33.6% from the October 31st total of 391,800 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC acquired a new stake in SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by institutional investors and hedge funds.

SciSparc Price Performance

Shares of SciSparc stock traded down $0.01 on Friday, hitting $0.21. The stock had a trading volume of 156,131 shares, compared to its average volume of 427,793. The business’s 50 day moving average is $0.23 and its two-hundred day moving average is $0.51. SciSparc has a twelve month low of $0.21 and a twelve month high of $9.80.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.